Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Immatics N.V.NASDAQ: IMTX

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -€286.55M, compared with -€224.46M a year earlier.

Context

  • Net debt amounted to 52.7% of total assets at the end of Q1 FY2026, up 17.7 pp from a year earlier.
  • Net debt grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -27.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€286.55M+13.2% QoQ
Last fiscal yearDec 2025
-€330.14M-49.7% YoY
Year agoMar 2025
-€224.46M-27.7% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.7%——
1 year-49.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

EUR · from the balance sheet

Latest · FY2025
(330.14M) EUR
Year-over-year change
-49.7%

Net Debt vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -27.7% is the 8th highest of 11, against a peer median of +32.2%.
  • Net debt amounts to 52.7% of total assets for IMTX, versus a peer median of 15.1%.
IMTX Competitors
Net Debt for IMTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026$73.6M USD+305.2%—25.5%
ALLOAllogene Therapeutics, Inc.Mar 2026$50.74M USD+30.7%-7.0%12.8%
ATRAAtara Biotherapeutics, Inc.Mar 2026$1.73M USD-95.8%—8.7%
IMCRImmunocore Holdings plcMar 2026-$16.99M USD+60.3%—1.6%
JANXJanux Therapeutics, Inc.Mar 2026-$30.26M USD+40.8%—2.9%
TCRXTScan Therapeutics, Inc.Mar 2026-$35.52M USD+37.8%—17.6%
LYELLyell Immunopharma, Inc.Mar 2026-$41.92M USD+33.7%—12.0%
DTILPrecision BioSciences, Inc.Mar 2026-$70.9M USD-49.4%—49.3%
IMTXImmatics N.V.Mar 2026-€286.55M EUR-27.7%—52.7%
LEGNLegend Biotech CorporationSep 2026-$293.3M USD-323.3%—17.4%
BNTXBioNTech SEJun 2026-€9.42B EUR+5.8%—46.3%
Peer median (excluding IMTX) —+32.2%-7.0%15.1%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents132.99M148.52M218.47M236.75M345.77M
Short-term Investments12.12M213.69M207.42M367.7M123.37M
Net Receivables2.36M1.11M5.74M6.75M6.88M
Inventory00000
Other Current Assets950K13.84M7.12M6.31M14.86M
Total Current Assets152.21M377.15M449.37M629.56M503.79M
Property, Plant & Equipment (Net)20.49M26.49M57.06M63.71M54.87M
Goodwill00000
Intangible Assets1.32M1.63M1.52M1.63M1.58M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets636K2.55M2.02M1.25M1.85M
Total Non-current Assets22.44M30.67M60.6M66.59M58.3M
Total Assets174.65M407.82M509.97M696.15M562.1M
Account Payables3.01M4.03M7.67M10.11M339.86K
Short-term Debt00002.76M
Tax Payables1.76M7.72M7.86M3.77M0
Deferred Revenue50.4M64.96M100.4M35.91M15.81M
Other Current Liabilities28.04M17.88M20.48M4.77M2.81M
Total Current Liabilities95.15M106.45M156.55M67.99M42.99M
Long-term Debt00000
Deferred Tax Liabilities0005.8M3.81M
Deferred Revenue (Non-current)48.23M75.76M115.53M34.16M18.53M
Other Non-current Liabilities68K42K115.53M00
Total Non-current Liabilities55.44M88.2M128.33M53.32M35.21M
Total Liabilities150.58M194.66M284.88M121.3M78.2M
Common Stock629K767K847K1.22M1.34M
Retained Earnings(537.81M)(500.3M)(597.29M)(589.54M)(785.65M)
Accumulated OCI(3.95M)(1.48M)(1.64M)1.03M(8.59M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity24.06M213.16M225.08M574.84M483.89M
Total Debt9.85M14.56M15.4M16.2M15.63M
Net Debt(123.14M)(133.96M)(203.07M)(220.55M)(330.14M)

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.